Actinogen Medical Ltd
(ASX:ACW) says its patent for a drug called ‘Xanamem’ has been extended in the US.
Xanamem is used to inhibit excess production of a stress hormone, called cortisol, which the company says is linked with cognitive decline.
This patent (US 9,365,564 B2) protects the use of Xanamem for use in Alzhemier’s disease and other related illnesses.
The company says this patent will be in place for the next 15 years – until 2031. According to the company, this is significant because the US represents half of the global Alzheimer’s disease treatment market.
Actinogen reported a net loss of $1.2 million at 31 December 2015.
